Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer an... | Stopped
Safety of SGI-1776, A PIM Kinase In... | Stopped
Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Prostate Cancer
  • Non-Hodgkins Lymphoma
Primary Contact Details
Unfortunately contact details are not available for this trial.
Recruitment Status
Stopped
Trial source and source ID number
NCT00848601

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
Patients with hormone and docetaxel refractory prostate cancer or relapsed/refractory non-Hodgkin's lymphoma for which no available standard therapy or therapy which may provide clinical benefit is available will be enrolled. Primary objectives: estimate the maximum tolerated dose and dose-limiting toxicities. Secondary objectives: Response rate, pharmacokinetic and pharmacodynamic profiles, Prostate Specific Antigen response and renal elimination.
Research Details
    Sorry, this information is not available
Phase
Phase 1
Study Design
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label
Study Type
Interventional
Intervention
Drug : SGI-1776
Intervention Type
See Interventions above
Primary Outcome Measures
    MTD & DLT; July 2011
Secondary Outcome Measures
    Response rate, pharmacokinetics, PSA response, renal elimination and pharmacodynamic effects on biomarker modulation.; July 2011
Publication(s)
Sorry, this information is not available
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
18 Years - N/A
Who Can Participate
Patients
Number of Participants
Sorry, this information is not available
Participant Inclusion Criteria
    General

    Inclusion Criteria:

    1. Read, understand and sign the IRB- or IEC-approved ICF confirming his or her willingness to participate in this trial.

    2. At least 18 years old.

    3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

    4. Adequate bone marrow function; normal renal and hepatic function, normal cardiac function.

    5. Normal cardiac function in the opinion of the investigator and supported by LVEF 50% or greater on the screening echocardiogram (or MUGA), no significant abnormalities on the screening ECG (eg, left bundle branch block, III degree AV block, acute myocardial infarction, Wolff-Parkinson-White syndrome or QTc interval ≥ 450 msec) and no history of additional risk factors for torsades de pointes (eg, heart failure, hypokalemia or family history of Long QT Syndrome).

    Exclusion Criteria:

    1. Active secondary malignancy or history of other malignancy within the last two years except non-melanoma skin cancers or cervical carcinoma in situ.

    2. History of significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure and/or myocardial infarction or any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification.

    3. Received any anticancer agent(s) within the past 3 weeks, including investigational agents, chemotherapy (6 weeks for nitrosoureas or mitomycin), immunotherapy, biologic or marketed or investigational tyrosine kinase inhibitors.

    4. Received prior radiation therapy within the past 4 weeks or received irradiation of ≥ 25% of their bone marrow reserve.

    5. Any serious, uncontrolled active infection that requires systemic treatment or known infection with HIV, HCV or HBV.

    6. Symptomatic CNS metastases or lesions for which treatment is required.

    Prostate Cancer

    Inclusion Criteria:

    1. Males with histologically confirmed adenocarcinoma of the prostate, which is now metastatic (e.g., any T, any N, M1a-c)based on bone scan, CT scan, or MRI scan. Demonstrated evidence of progressive disease despite androgen deprivation (androgen ablation or surgical castration), anti-androgen withdrawal and progression of disease after docetaxel-based therapy.

    2. Demonstrated evidence of progressive disease despite androgen deprivation (androgen ablation or surgical castration), anti-androgen withdrawal and progression of disease after docetaxel-based therapy.

    • Greater than 25% increase in 3 consecutive tests (PSA 1 < PSA 2 < PSA 3), each PSA value separated by at least 1 week

    3. Serum testosterone level ≤ 50 ng/dL post orchiectomy or while maintained on continuous or intermittent medical androgen suppression with a LHRH agonist or antagonist.

    4. At least 4 weeks since prior flutamide, megestrol, ketoconazole, aminoglutethimide; and at least 6 weeks since prior bicalutamide or nilutamide.

    5. Systemic corticosteroids discontinued within two weeks of dosing, except low dose regimens which may continue if unchanged

    6. Strontium-89 or Samarium-153 must have been completed at least 8 weeks prior to the first dose of therapy and recovered from all treatment-related toxicities.

    Exclusion Criteria:

    1. Must not be receiving concurrent anti-androgen hormonal therapy for hormone refractory prostate cancer.

    Non-Hodgkin's Lymphoma

    Inclusion Criteria:

    1. Histologically proven relapsed or refractory non-Hodgkin's lymphoma subjects for which there is no available standard therapy or therapy which may provide clinical benefit.

    2. Measurable disease (at least 1 lesion ≥ 1.5 cm).

    Exclusion Criteria:

    1. Bulky disease by CT, defined as any single mass >10 cm in its greatest diameter.

    2. Systemic corticosteroids within 2 weeks, except low dose regimens which may continue if unchanged.

    3. Received any radiopharmaceutical therapy within the past six weeks.
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Royal Marsden - Surrey
Sutton
England
SM2 5PT
Trial Contact(s)
Primary Trial Contact
Sorry, this information is not available
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom, United States
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Hormone and Docetaxel Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
EudraCT Number
Not available for this trial
Funder(s)
    Sorry, this information is not available
Other Study ID Numbers
SGI-1776-01
Sponsor(s)
Astex Pharmaceuticals
Key Dates

Recruitment Start Date

Feb 2009

Recruitment End Date

Oct 2010

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

19 Feb 2009

Date updated in source

01 Dec 2011